Gait Improvement by Low-dose Botulinum Toxin A Injection Treatment of the Lower Limbs in Subacute Stroke Patients

Overview

Journal J Phys Ther Sci

Date 2015 May 2

PMID 25931725

Citations 17

Authors

Wu Tao

Dong Yan

Jian-Hua Li

Zhao-Hong Shi

Affiliations

Soon will be listed here.

Abstract

[Purpose] Lower-limb spasticity after stroke may be associated with worse functional outcome. Our study aim was to establish whether a low-dose botulinum toxin A (BTX-A) injection in subacute stroke patients can improve spasticity, gait, and daily living abilities. [Subjects] Twenty-three subacute stroke patients were randomly allocated to BTX-A treatment group (11 patients) and control group (12 patients). [Methods] In the BTX-A treatment group patients, 200 units BTX-A was injected into the triceps surae (150 iu) and posterior tibial (50 iu) by electrical stimulation-guided. The patients in the control group received the same volume of placebo solution into the same injection locations. Gait analysis (step length, cadence, speed), the 6-min walking test, Fugl-Meyer Assessment (FMA) of the lower limbs, modified Ashworth scale assess (MAS) assessment of the lower limbs, surface electromyography (sEMG), and modified Barthel index (MBI) assessment were performed before and at 4,8 weeks after treatment. [Results] We found that the FMA of the low limbs and MBI were significantly improved in both groups. The gait analysis, FMA, and MBI results in the BTX-A treatment group were better than those in the control group. MAS and surface electromyography (sEMG) showed better improvement of spasticity in the treatment group. [Conclusion] Early low-dose botulinum toxin A (BTX-A) injection in subacute stroke patients into the lower-limb may improve gait, spasticity, and daily living abilities.

Citing Articles

Long-Term Management of Post-Stroke Spasticity with Botulinum Toxin: A Retrospective Study.

Falcone N, Leo F, Chisari C, Dalise S Toxins (Basel). 2024; 16(9).

PMID: 39330841 PMC: 11436082. DOI: 10.3390/toxins16090383.

Gait Reconstruction Strategy Using Botulinum Toxin Therapy Combined with Rehabilitation.

Hara T, Takekawa T, Abo M Toxins (Basel). 2024; 16(7).

PMID: 39057963 PMC: 11281298. DOI: 10.3390/toxins16070323.

Efficiency of botulinum toxin injection into the arm on postural balance and gait after stroke.

Lee J, Park J, Kang B, Yang S Sci Rep. 2023; 13(1):8426.

PMID: 37225852 PMC: 10209164. DOI: 10.1038/s41598-023-35562-1.

Efficacy on gait and posture control after botulinum toxin A injection for lower-limb spasticity treatment after stroke: A randomized controlled trial.

Yu H, Liu S, Wang Z, Liu C, Dai P, Zang D Front Neurosci. 2023; 16:1107688.

PMID: 36726851 PMC: 9884969. DOI: 10.3389/fnins.2022.1107688.

Early Use of Phenol Neurolysis Likely Reduces the Total Amount of Botulinum Toxin in Management of Post-Stroke Spasticity.

Li S, Woo J, Mas M Front Rehabil Sci. 2022; 2:729178.

PMID: 36188807 PMC: 9397677. DOI: 10.3389/fresc.2021.729178.

References

Ferreira L, Neto H, Grecco L, Christovao T, Duarte N, Lazzari R . Effect of Ankle-foot Orthosis on Gait Velocity and Cadence of Stroke Patients: A Systematic Review. J Phys Ther Sci. 2014; 25(11):1503-8. PMC: 3881487. DOI: 10.1589/jpts.25.1503. View

Kanovsky P, Slawek J, Denes Z, Platz T, Sassin I, Comes G . Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol. 2009; 32(5):259-65. DOI: 10.1097/WNF.0b013e3181b13308. View

Sommerfeld D, Eek E, Svensson A, Holmqvist L, von Arbin M . Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke. 2003; 35(1):134-9. DOI: 10.1161/01.STR.0000105386.05173.5E. View

Speelman J . Treatment strategies in movement disorders. J Inherit Metab Dis. 2005; 28(3):441-4. DOI: 10.1007/s10545-005-8049-9. View

Lundstrom E, Smits A, Terent A, Borg J . Time-course and determinants of spasticity during the first six months following first-ever stroke. J Rehabil Med. 2010; 42(4):296-301. DOI: 10.2340/16501977-0509. View

McIntyre A, Lee T, Janzen S, Mays R, Mehta S, Teasell R . Systematic review of the effectiveness of pharmacological interventions in the treatment of spasticity of the hemiparetic lower extremity more than six months post stroke. Top Stroke Rehabil. 2012; 19(6):479-90. DOI: 10.1310/tsr1906-479. View

Tomita Y, Usuda S . Temporal motor coordination in the ankle joint following upper motor neuron lesions. J Phys Ther Sci. 2013; 25(5):539-44. PMC: 3804970. DOI: 10.1589/jpts.25.539. View

Urban P, Wolf T, Uebele M, Marx J, Vogt T, Stoeter P . Occurence and clinical predictors of spasticity after ischemic stroke. Stroke. 2010; 41(9):2016-20. DOI: 10.1161/STROKEAHA.110.581991. View

Ward A . Spasticity treatment with botulinum toxins. J Neural Transm (Vienna). 2008; 115(4):607-16. DOI: 10.1007/s00702-007-0833-2. View

10.

Kong K, Chua K, Lee J . Symptomatic upper limb spasticity in patients with chronic stroke attending a rehabilitation clinic: frequency, clinical correlates and predictors. J Rehabil Med. 2010; 42(5):453-7. DOI: 10.2340/16501977-0545. View

11.

Cousins E, Ward A, Roffe C, Rimington L, Pandyan A . Does low-dose botulinum toxin help the recovery of arm function when given early after stroke? A phase II randomized controlled pilot study to estimate effect size. Clin Rehabil. 2010; 24(6):501-13. DOI: 10.1177/0269215509358945. View

12.

Lundstrom E, Terent A, Borg J . Prevalence of disabling spasticity 1 year after first-ever stroke. Eur J Neurol. 2008; 15(6):533-9. DOI: 10.1111/j.1468-1331.2008.02114.x. View

13.

van Kuijk A, Hendricks H, Pasman J, Kremer B, Geurts A . Are clinical characteristics associated with upper-extremity hypertonia in severe ischaemic supratentorial stroke?. J Rehabil Med. 2007; 39(1):33-7. DOI: 10.2340/16501977-0009. View

14.

Borg J, Ward A, Wissel J, Kulkarni J, Sakel M, Ertzgaard P . Rationale and design of a multicentre, double-blind, prospective, randomized, European and Canadian study: evaluating patient outcomes and costs of managing adults with post-stroke focal spasticity. J Rehabil Med. 2010; 43(1):15-22. DOI: 10.2340/16501977-0663. View

15.

Pandyan A, Gregoric M, Barnes M, Wood D, van Wijck F, Burridge J . Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil. 2005; 27(1-2):2-6. DOI: 10.1080/09638280400014576. View

16.

Mancini F, Sandrini G, Moglia A, Nappi G, Pacchetti C . A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci. 2005; 26(1):26-31. DOI: 10.1007/s10072-005-0378-9. View

17.

Rosales R, Chua-Yap A . Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. J Neural Transm (Vienna). 2008; 115(4):617-23. DOI: 10.1007/s00702-007-0869-3. View

18.

Santamato A, Micello M, Panza F, Fortunato F, Pilotto A, Giustini A . Safety and efficacy of incobotulinum toxin type A (NT 201-Xeomin) for the treatment of post-stroke lower limb spasticity: a prospective open-label study. Eur J Phys Rehabil Med. 2013; 49(4):483-9. View

19.

Cosgrove A, Graham H . Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse. Dev Med Child Neurol. 1994; 36(5):379-85. DOI: 10.1111/j.1469-8749.1994.tb11863.x. View

20.

Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M . Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol. 2010; 257(8):1330-7. PMC: 2910313. DOI: 10.1007/s00415-010-5526-3. View